Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

13 Feb 2017

Abstract excerpt

Small cell lung cancer (SCLC) is a highly aggressive malignancy with few therapeutic advances in the treatment in recent decades. Based on a recent study that identified the spliceosome as a therapeutic vulnerability in MYC-driven breast cancers, we evaluated the efficacy of a spliceosome inhibitor in SCLC cell lines and analyzed the correlation with MYC status. Among 23 SCLC cell lines examined, eight showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28192473
DOI: 10.1371/journal.pone.0172209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusPMID 28192473Read ↗

The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung CancerSemantic proximity Read ↗

Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancerSemantic proximity Read ↗

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionSemantic proximity Read ↗

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.Semantic proximity Read ↗

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivationSemantic proximity Read ↗

Natural Compound Library Screening Identifies Sanguinarine Chloride For The Treatment of SCLC By Upregulating CDKN1ASemantic proximity Read ↗

β-Elemene prevented cisplatin resistance of small cell lung cancer cell H446 by regulating MiR-199a-5p-mediated autophagySemantic proximity Read ↗

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung CancerSemantic proximity Read ↗

A story of MiR-199a-5p in small cell lung cancer cisplatin resistanceSemantic proximity Read ↗

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathwaySemantic proximity Read ↗

β-Elemene Prevented Multidrug Resistance of Small Cell Lung Cancer Cell Line H446: Targeting the Autophagy Regulation of MiR-199a-5p is the Mechanism of Cisplatin Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.